厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效

摘要

1文献来源研究一:Nakagawa K,Garon EB,Seto T,et al.Ramucirumab plus Erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(12):1655-1669.研究二:Zhou Q,Wu YL,Cheng Y,et al.CTONG 1509:Phase 3 study of Erlotinib with or without Bevacizumab in untreated Chinese patients with advanced EGFR-mutated NSCLC[J].Ann Oncol,2019,30(5S):v602-v660.2证据水平1b。3背景临床前和临床研究证实厄洛替尼联合抗血管生成药物具有协同作用,可显著延长表皮生长因子受体(epidermal growth factor receptor,EGFR)敏感突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的无进展生存期(progression-free survival,PFS)。